Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
March 13, 2018 07:30 ET
|
Epizyme, Inc.
First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019 Multiple Phase 2 Study Data...
Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
March 12, 2018 16:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the appointment of...
Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference
March 12, 2018 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation at the Cowen 38th Annual Health Care Conference
February 27, 2018 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme to Participate in Leerink Partners 7th Annual Global Healthcare Conference
February 07, 2018 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
December 11, 2017 07:31 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel...
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting
December 10, 2017 10:00 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two...
Epizyme to Present at the Jefferies 2017 London Healthcare Conference
November 09, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates
November 01, 2017 16:02 ET
|
Epizyme, Inc.
Company Scheduled for First FDA Interaction for Tazemetostat in NHL in 4Q17 Chief Medical Officer, Dr. Peter Ho, to Transition from Epizyme at the End of 2017; Will Continue to Support Upcoming...
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2017 09:15 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced encouraging data from...